TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26420671

Group type: EXPERIMENTAL
Intervention: Continuing medical education workshop (See One)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Apprenticeship model with live supervision (Do One)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ordering MI from psychiatry consultation‐liaison service (Order One)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study: 23837810

Group type: EXPERIMENTAL
Intervention: Popular Opinion Leader (POL) intervention
Number of subjects: 880

Group type: COMPARATOR
Intervention: Non-POL providers (Control)
Number of subjects: 880
Study: 21724580

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (800 IU/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g/d)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 19410250

Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (non-periodontitis)
Number of subjects: 101
Study: 17492350

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Conjugated Hib vaccine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (T)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HM group
Number of subjects: 44
Study: 15145966

Group type: EXPERIMENTAL
Intervention: Anidulafungin 50 mg, 75 mg, or 100 mg daily intravenous infusions preceded by a loading dose that was twice the daily dose.
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 225
Study: 11467870

Group type: EXPERIMENTAL
Intervention: Dilute Calogen
Number of subjects: 71

Group type: COMPARATOR
Intervention: Water
Number of subjects: 71

Group type: COMPARATOR
Intervention: 2% sodium diatrizoate
Number of subjects: 71
Study: 8770428

Group type: EXPERIMENTAL
Intervention: Regular neuroleptic medication
Number of subjects: 71

Group type: COMPARATOR
Intervention: Withdrawal from medication
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Life events
Number of subjects: 71
Study: 1581815

Group type: EXPERIMENTAL
Intervention: Norfloxacin prophylaxis
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cefuroxime prophylaxis
Number of subjects: 140

Group type: COMPARATOR
Intervention: No antibiotic cover
Number of subjects: 140
Study: 3882270

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 12
Study: 30833310

Group type: EXPERIMENTAL
Intervention: Camera-based mirror visual feedback (camMVF) intervention group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Shielded mirror visual feedback intervention group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapy group
Number of subjects: 90
Study: 30114680

Group type: EXPERIMENTAL
Intervention: Good School Toolkit intervention
Number of subjects: 3820
Study: 27687456

Group type: EXPERIMENTAL
Intervention: Pleth Variability Index (PVI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Esophageal Doppler
Number of subjects: 40
Study: 25592946

Group type: EXPERIMENTAL
Intervention: Huxin Formula
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 270
Study: 22545895

Group type: EXPERIMENTAL
Intervention: PEVI + anticoagulation
Number of subjects: 183

Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 183
Study: 19851098

Group type: EXPERIMENTAL
Intervention: Nasal bridling of feeding tubes
Number of subjects: 80
Study: 17933158

Group type: EXPERIMENTAL
Intervention: Milrinone (bolus and infusion throughout surgery)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 88
Study: 15615752

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling
Number of subjects: 40

Group type: COMPARATOR
Intervention: Further macular laser
Number of subjects: 40
Study: 12149533

Group type: EXPERIMENTAL
Intervention: AS+NRT (Nicotine patches daily and inhalator as needed plus advice and support)
Number of subjects: 245

Group type: COMPARATOR
Intervention: AS (Advice and support only)
Number of subjects: 245
Study: 10431581

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade alone (Group-A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Combined androgen blockade with UFT (Group-B)
Number of subjects: 44
Study: 8775649

Group type: EXPERIMENTAL
Intervention: Sexual intercourse 12 hours prior to maximal treadmill exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: No sexual intercourse prior to maximal treadmill exercise
Number of subjects: 11
Study: 1934240

Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg body weight twice daily) for 1 day (3 doses)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg body weight twice daily) for 2 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg body weight twice daily) for 4 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg body weight twice daily) for 7 days
Number of subjects: 64
Study: 7106043

Group type: EXPERIMENTAL
Intervention: Bicycle ergometer load for 10 minutes (group I)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 20-percent lipofundin followed by ergometer load (group II)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intravenous infusion of lipofundin without subsequent physical stress (group III)
Number of subjects: 35
Study: 30770763

Group type: EXPERIMENTAL
Intervention: Combined pain competence and depression prevention training (Intervention Group)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Pain competence training (Control Group)
Number of subjects: 583
Study: 28181128

Group type: EXPERIMENTAL
Intervention: 12-week exercise program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Relaxation control group
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 160
Study: 27085783

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change aimed at achieving 7% weight loss
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: Metformin 850mg twice daily
Number of subjects: 3070

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3070
Study: 24879138

Group type: EXPERIMENTAL
Intervention: S-O clip-assisted ESD
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 70
Study: 21592974

Group type: EXPERIMENTAL
Intervention: UACR in the fourth quartile (≥ 6.1 mg/g)
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: UACR in the third quartile (3.8-6.1 mg/g)
Number of subjects: 1272

Group type: COMPARATOR
Intervention: UACR in the lowest quartile (<2.8 mg/g)
Number of subjects: 1272
Study: 19165497

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic fundoplication (RALF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional laparoscopic fundoplication (CLF)
Number of subjects: 40
Study: 17122382

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 5 mg twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 10 mg twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15259618

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patients with sleep apnea syndrome
Number of subjects: 16
Study: 11244190

Group type: EXPERIMENTAL
Intervention: HDF three times per week (Group 3)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: HDF (duration > 12 months)
Number of subjects: 112

Group type: COMPARATOR
Intervention: HDF
Number of subjects: 112
Study: 9558692

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy for rate control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy for rhythm control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug selection algorithm for rate control
Number of subjects: 0
Study: 7992236

Group type: EXPERIMENTAL
Intervention: Running velocity at anaerobic threshold (VAT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Running velocity at 95% of blood lactate concentration of 4 mM (V4mM)
Number of subjects: 16
Study: 3044507

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 0
Study: 31880009

Group type: EXPERIMENTAL
Intervention: mHealth intervention (TeenPower) for 6 months in addition to a school-based intervention
Number of subjects: 0
Study: 31655496

Group type: EXPERIMENTAL
Intervention: Prednisone administration
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Prednisolone administration
Number of subjects: 2

Group type: COMPARATOR
Intervention: GC-C-IRMS method
Number of subjects: 2
Study: 28222999

Group type: EXPERIMENTAL
Intervention: Stepwise, interactive education intervention (prenatally, postnatally, and 1 month after birth)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group received a leaflet containing general information on immunization
Number of subjects: 188
Study: 26674499

Group type: EXPERIMENTAL
Intervention: Daily 400 IU vitamin D supplementation
Number of subjects: 3012
Study: 23095610

Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion
Number of subjects: 475

Group type: COMPARATOR
Intervention: Autologous blood transfusion
Number of subjects: 475
Study: 20105697

Group type: EXPERIMENTAL
Intervention: Insomnia or daytime fatigue with MetS
Number of subjects: 2753

Group type: EXPERIMENTAL
Intervention: Insufficient sleep with MetS
Number of subjects: 2753

Group type: COMPARATOR
Intervention: MetS only
Number of subjects: 2753

Group type: EXPERIMENTAL
Intervention: Insufficient sleep and MetS
Number of subjects: 2753
Study: 17510001

Group type: EXPERIMENTAL
Intervention: 17-item asthma-specific questionnaire with pharmacist interaction (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care only (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16243339

Group type: EXPERIMENTAL
Intervention: Calcium (600 mg) plus CLA (450 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12374334

Group type: EXPERIMENTAL
Intervention: 330-340-nm excitation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 350-380-nm excitation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 400-450-nm excitation
Number of subjects: 146
Study: 10333943

Group type: EXPERIMENTAL
Intervention: Fasting 32,33 split proinsulin
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Fasting glucose concentration
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Intact proinsulin
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Combination of family history, fasting glucose, and total proinsulin
Number of subjects: 1071
Study: 8704653

Group type: EXPERIMENTAL
Intervention: Long-term head and neck cancer survivors
Number of subjects: 204

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 204
Study: 2190549

Group type: EXPERIMENTAL
Intervention: 30 mg pyridostigmine bromide every 8 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 379704

Group type: EXPERIMENTAL
Intervention: Carfecillin (250 mg and 500 mg p.o.)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Carfecillin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Indanyl ester of carbenicillin (control)
Number of subjects: 26
Study: 31389531

Group type: EXPERIMENTAL
Intervention: Cases of aggression perpetrated by unknown assailants
Number of subjects: 787
Study: 29045800

Group type: EXPERIMENTAL
Intervention: Immediate loading group (n = 81)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Delayed loading group (n = 77)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 158

Group type: COMPARATOR
Intervention: Immediate loading group vs Delayed loading group
Number of subjects: 158
Study: 27123977

Group type: EXPERIMENTAL
Intervention: Cognitive therapy based on the catastrophic cognitions model of PDA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Guided mastery (guided exposure) therapy based on the self-efficacy model of PDA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 46
Study: 25161302

Group type: EXPERIMENTAL
Intervention: Peripheral targeted nebulization
Number of subjects: 6

Group type: COMPARATOR
Intervention: Central targeted nebulization
Number of subjects: 6
Study: 22198639

Group type: EXPERIMENTAL
Intervention: 12-week once-a-week prolonged strength-training programme
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 95
Study: 20142220

Group type: EXPERIMENTAL
Intervention: Resolute stent
Number of subjects: 139
Study: 18499791

Group type: EXPERIMENTAL
Intervention: Presence of cerebral microbleeds in patients with ICH
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Number of microbleeds in patients with ICH
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: INR levels in patients with ICH
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Frequency of hypertension in patients with ICH
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Presence of cerebral microbleeds as a risk factor for ICH
Number of subjects: 87
Study: 16129216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study: 12167391

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959
Study: 9892856

Group type: EXPERIMENTAL
Intervention: Amisulpride (50 mg/day)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Amineptine (200 mg/day)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 323
Study: 7585283

Group type: EXPERIMENTAL
Intervention: Lipid-lowering diet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diet plus cholestyramine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual cardiac care
Number of subjects: 90
Study: 2272192

Group type: EXPERIMENTAL
Intervention: 0.5 mg etizolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7026401

Group type: EXPERIMENTAL
Intervention: Portal-systemic shunt (PSS)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 53
Study: 31852444

Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (ADF)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 271
Study: 28698258

Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard-dose enoxaparin
Number of subjects: 1000
Study: 26408319

Group type: EXPERIMENTAL
Intervention: Yerba Mate supplementation (3 g/day, 3 capsules per meal, 3 times a day for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23506627

Group type: EXPERIMENTAL
Intervention: Residual protein/creatinine ratio (rPCR) <1000 mg/g
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Residual estimated glomerular filtration rate (reGFR) ≥45 mL/min per 1.73 m2
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Residual protein/creatinine ratio (rPCR) between 1000-<2000 mg/g and reGFR ≥30 mL/min per 1.73 m2
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Residual estimated glomerular filtration rate (reGFR) <30 mL/min per 1.73 m2 and rPCR ≥2000 mg/g
Number of subjects: 1245
Study: 21946475

Group type: EXPERIMENTAL
Intervention: Individual training (group A)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Group training (group B)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Self-learning (group C)
Number of subjects: 95
Study: 19445552

Group type: EXPERIMENTAL
Intervention: Sublingual morphine sulphate 0.5 mg/kg (Group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sublingual midazolam 0.03 mg/kg (Group B)
Number of subjects: 29
Study: 18508950

Group type: EXPERIMENTAL
Intervention: Taranabant 5 mg once daily for 14 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Taranabant 7.5 mg once daily for 14 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Taranabant 10 mg once daily for 14 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Taranabant 25 mg once daily for 14 days
Number of subjects: 60
Study: 16077888

Group type: EXPERIMENTAL
Intervention: Antibiotics and G-CSF (group A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Antibiotics only (group B)
Number of subjects: 35
Study: 11849419

Group type: EXPERIMENTAL
Intervention: Tidal peritoneal dialysis (TPD)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Continuous equilibrating peritoneal dialysis (CEPD)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: TPD
Number of subjects: 87

Group type: COMPARATOR
Intervention: CEPD
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Kt/V
Number of subjects: 87
Study: 10215975

Group type: EXPERIMENTAL
Intervention: Group psycho-educational intervention (PEI) facilitated by a nurse in the community, three sessions
Number of subjects: 252
Study: 7484022

Group type: EXPERIMENTAL
Intervention: Adenosine 50-80 micrograms.kg-1.min-1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Morphine 0.1 mg.kg-1
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Adenosine 50 micrograms.kg-1.min-1 + Morphine 0.1 mg.kg-1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ketamine 0.1 mg.kg-1
Number of subjects: 26
Study: 2198848

Group type: EXPERIMENTAL
Intervention: Pancrease
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Creon
Number of subjects: 39
Study: 364021

Group type: EXPERIMENTAL
Intervention: Antimycotic denture adhesive (amphotericin medicated adhesive)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo denture adhesive
Number of subjects: 70
Study: 31556001

Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 152

Group type: COMPARATOR
Intervention: CVC
Number of subjects: 152
Study: 30203412

Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 22

Group type: COMPARATOR
Intervention: Uncemented total hip arthroplasty
Number of subjects: 22
Study: 28327696

Group type: EXPERIMENTAL
Intervention: 0.5 mm subcrestal implant placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1.5 mm subcrestal implant placement
Number of subjects: 60
Study: 25833966

Group type: EXPERIMENTAL
Intervention: Microdecompression
Number of subjects: 885

Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 885
Study: 22806557

Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program
Number of subjects: 33152

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33152
Study: 21335622

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1089
Study: 19126187

Group type: EXPERIMENTAL
Intervention: Active rapid rate lumbosacral magnetic stimulation (rLSMS) at 15 Hz, 100% output intensity for 5 s min(‐1) for 30 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham rapid rate lumbosacral magnetic stimulation (rLSMS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Active rapid rate lumbosacral magnetic stimulation (rLSMS)
Number of subjects: 12
Study: 17531896

Group type: EXPERIMENTAL
Intervention: Spontaneous preterm birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indicated preterm birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors modifying risk
Number of subjects: 0
Study: 15533378

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran (Dextran 40) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human albumin infusion
Number of subjects: 0
Study: 11486851

Group type: EXPERIMENTAL
Intervention: Vacuum assisted drainage (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Centrifugal pump venous aspiration (Group B)
Number of subjects: 50
Study: 9623383

Group type: EXPERIMENTAL
Intervention: Day-case management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overnight admission
Number of subjects: 100
Study: 7839774

Group type: EXPERIMENTAL
Intervention: TIVA with propofol and alfentanil (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Balanced anaesthesia (BA) with isoflurane/N2O/fentanyl (n = 15)
Number of subjects: 30
Study: 2904839

Group type: COMPARATOR
Intervention: Placebo tablet alone (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Placebo tablet with 150 ml oral fluid (Group 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral ranitidine 150 mg with oral fluid 150 ml (Group 4)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Placebo tablet with IM narcotic and atropine (Group 2)
Number of subjects: 120
Study: 31520294

Group type: EXPERIMENTAL
Intervention: Lutz sedimentation technique
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Modified Ritchie sedimentation technique
Number of subjects: 213

Group type: COMPARATOR
Intervention: Faust flotation technique
Number of subjects: 213

Group type: COMPARATOR
Intervention: Modified Sheather flotation technique
Number of subjects: 213
Study: 28652716

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 minutes, for 5 consecutive days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study: 26138864

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 23279720

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 2

Group type: COMPARATOR
Intervention: mFOLFOX-6
Number of subjects: 2
Study: 21251087

Group type: EXPERIMENTAL
Intervention: Virtual slides
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glass slides
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Virtual microscopy
Number of subjects: 10
Study: 18300148

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Clinical examination by senior pediatric orthopedists
Number of subjects: 536

Group type: COMPARATOR
Intervention: Graf's method
Number of subjects: 536